Lipocine's - LPCN market analysis on 27th November 2020

Transaction Date	Recipient	Shares	Type	Price	Value
17th March 2020	John W. Higuchi	220,000	Open or private purchase	$0.32	$69,542.00
31st December 2019	Mahesh V. Patel	40,000	Open or private purchase	$0.38	$15,340.00
10th December 2019	Mahesh V. Patel	25,000	Open or private purchase	$0.40	$9,975.00
4th December 2019	Mahesh V. Patel	145,000	Exercise of derivative	$0.00
4th December 2019	Morgan R Brown	17,250	Open or private sale	$0.41	$7,075.95
4th December 2019	Mahesh V. Patel	43,500	Open or private sale	$0.41	$17,835.00
4th December 2019	Morgan R Brown	57,500	Exercise of derivative	$0.00
26th November 2019	Mahesh V. Patel	1,100	Open or private purchase	$0.43	$469.70
26th November 2019	Mahesh V. Patel	21,928	Open or private purchase	$0.43	$9,385.18
26th November 2019	Mahesh V. Patel	1,272	Open or private purchase	$0.43	$542.51

Lipocine

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Lipocine, Inc. focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Ticker: LPCN

Sector: Health Technology

Industry: Pharmaceuticals: Other

SEC Central Index Key (CIK): 1535955

Employees: 12

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis